Maintenance chemotherapy showed no clear difference in 10‐year OS compared with maintenance radiotherapy (low certainty).
Chemotherapy + bevacizumab leads to lower overall survival compared with chemotherapy (high certainty).
Chemotherapy + bevacizumab leads to lower progression‐free survival compared with chemotherapy (high certainty).
Chemotherapy + bevacizumab leads to higher overall tumour response compared with chemotherapy (high certainty).
Chemotherapy + bevacizumab showed no clear difference in severe adverse effects compared with chemotherapy (low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious haemorrhage compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serious thromboembolic events compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).
Cediranib plus chemotherapy showed no clear difference in serious adverse events compared with placebo plus chemotherapy (low certainty).
The review found no eligible studies for this question.
Cediranib plus chemotherapy showed no clear difference in overall survival compared with placebo plus chemotherapy (low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).
It is very uncertain whether chemotherapy + ART changes complete Response to Tx compared with chemotherapy Alone (very low certainty).
It is very uncertain whether chemotherapy + ART changes complete/Partial Response to Tx compared with chemotherapy Alone (very low certainty).
It is very uncertain whether chemotherapy + ART changes complete Among Known Outcome compared with chemotherapy Alone (very low certainty).
It is very uncertain whether chemotherapy + ART changes complete/Partial Among Known Outcome compared with chemotherapy Alone (very low certainty).
It is very uncertain whether chemotherapy + ART changes mortality compared with chemotherapy Alone (very low certainty).
Bevacizumab plus chemotherapy may leads to lower overall survival compared with chemotherapy (low certainty).
Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).
Bevacizumab plus chemotherapy may leads to higher specific adverse events: serious haemorrhage compared with chemotherapy (low certainty).